Orchestra BioMed Holdings Inc — Cash Flow (NASDAQ:OBIO) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Cash from operating activities —-272.36 K-1.58 M-46.13 M-50.56 M-48.96 M -48.96 M Cash from investing activities —092.59 M10.69 M13.09 M-26.94 M -26.94 M Cash from financing activities —0-92.59 M46.22 M29.17 M88.33 M 88.33 M Free cash flow —-272.36 K-1.58 M-46.2 M-50.85 M-49.45 M -49.45 M

Nouvelles

Jefferies abaisse l’objectif de cours d’Orchestra BioMed en raison des coûts de financement

Chardan réitère sa recommandation sur Orchestra BioMed, focus sur les essais

Chardan reiterates Orchestra BioMed stock rating on trial focus

Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates

Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates

Orchestra BioMed to present hypertension therapy data at medical meetings

TD Cowen initie la couverture d’Orchestra BioMed avec une recommandation d’achat pour son portefeuille de dispositifs médicaux innovants

TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Medtronic reçoit l’approbation de la FDA pour un dispositif contre l’incontinence urinaire